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Abstract
Objectives—We present a novel, patient-centric, longitudinal summary of patient progress 
through the HIV care continuum. Using this new approach, we compare person-time spent alive, 
in care, on antiretroviral therapy (ART) and virally suppressed among persons who inject drugs 
(PWID) and those who do not (non-IDU).
Design—Prospective clinical observational cohort study.
Methods—We followed ART-naïve patients with detectable HIV viral loads who enrolled in the 
Johns Hopkins HIV Clinical Cohort from enrollment until the occurrence of several care 
continuum-related milestones, including ART initiation and viral suppression, and until several 
care continuum-related failures, including loss-to-clinic (LTC) and death. We added and subtracted 
cumulative incidence curves to estimate the proportion of the cohort in each of seven continuum 
stages across the 10 years following enrollment in clinical care.
Results—PWID composed 32% of the study sample (n=1,443). Over ten years following 
enrollment in care, PWID and non-IDU spent only 23% and 37% of person-time in care, on ART 
and virally suppressed. PWID lost 8.9 more months of life compared to non-IDU and spent an 
additional 5.0 months on ART but not virally suppressed, and an additional 5.5 months in care but 
not on ART. There were not meaningful improvements in the 5-year restricted mean person-time 
differences comparing PWID to non-IDU across enrollment cohorts (2000-03, 2004-07, 2008-14).
Conclusions—Efforts to increase viral suppression among PWID should focus on increasing 
ART initiation and improving adherence to therapy.
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Introduction
Viral suppression is the ultimate goal of HIV care, given the associated reduced morbidity, 
mortality and infectiousness [1, 2]. The HIV care continuum is a convenient framework for 
visualizing the path to viral suppression, and is typically presented as the proportion of HIV-
infected persons diagnosed, linked to medical care, retained in care, prescribed antiretroviral 
therapy (ART) and virally suppressed in a given population in a given year [3, 4]. The cross-
sectional care continuum does not address how individuals move through the continuum 
over time [5].
Injection drug use (IDU) is associated with poorer HIV-related outcomes [6, 7]. Particularly, 
people who inject drugs (PWID) experience delays linking to HIV medical care, and are less 
likely to be retained in care, prescribed ART and virally suppressed [8-10]. PWID also have 
a higher mortality risk than non-IDU [11, 12]. “Longitudinal” analyses of the care 
continuum are typically serial snapshots, with people who die removed from the 
denominator for continuum estimates in subsequent years [13], artificially inflating the 
reported proportion of PWID who are virally suppressed [14, 15]. Furthermore, excluding 
deceased persons precludes consideration of death as a relevant end-point for the care 
continuum.
We present a novel method for visualizing the care continuum for PWID and non-IDU, 
subsequent to engagement in care which accounts for differences in survival and shifts 
consideration of the care continuum from a cross-sectional to a longitudinal perspective.
METHODS
Study population
The Johns Hopkins HIV Clinic provides HIV continuity care to HIV-infected persons 
principally residing in the Baltimore, Maryland area, but also from surrounding states. HIV-
infected patients both self-refer and are referred to the clinic by other health care providers 
across the region. Patients are enrolled into care without regard to demographic, 
socioeconomic status or medical insurance and the clinic population reflects the HIV 
epidemic in Baltimore and the surrounding region. The clinic is staffed by pharmacists, 
nurses and caseworkers that supports antiretroviral adherence through methods tailored to 
the individual patient. The Johns Hopkins HIV Clinical Cohort (JHHCC) consists of all 
HIV-infected persons age ≥18 years who enroll in care at Johns Hopkins HIV clinic and 
consent to share their data (>90% of persons enrolled into continuity care). For this study, 
we included persons enrolled in the JHHCC from January 2000 to August 2015 who were 
ART naïve (prior exposure to mono- or dual- therapy only) and not virally suppressed (≤400 
copies/mL) at enrollment. Collection of data on patients in the JHHCC, and this analysis, 
were approved by the Johns Hopkins Hospital Institutional Review Board.
Patients who reported IDU as the likely source of their HIV infection (i.e., who had a history 
of injection prior to their HIV diagnosis) were classified as PWID. PWID may not have been 
actively injecting throughout the study period. Furthermore, non-IDU may have been using 
illicit drugs through routes other than injection (it is possible but unlikely that some patients 
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started injecting drugs after enrollment). Heroin and cocaine are the most commonly 
injected drugs in this cohort; injection of amphetamine and other drugs is rare. Baseline 
laboratory values were defined as those measured closest to enrollment, within a window 6 
months prior to and 1 month after enrollment. We excluded 14 patients without baseline 
CD4 cell count.
Outcomes measurement
Because our study sample was, by definition, linked to care, we focused on care continuum 
outcomes subsequent to linkage to care: loss-to-care, ART initiation, viral suppression, and 
death. We stratified death and loss-to-care by whether they occurred before or after ART 
initiation. Thus there were seven care continuum stages in our framework (listed below; also 
in Appendix A, Figure 1). Loss-to-care was approximated as loss-to-clinic (LTC), with the 
understanding that patients lost to the Johns Hopkins HIV clinic may reengage in care 
elsewhere. Patients were classified as LTC after 12 months with no HIV laboratory 
measurements or clinical visits in the HIV outpatient center. Patients re-entered care with 
any new CD4 count, viral load or clinical visit. ART initiation was defined as the initiation 
of ≥3 antiretroviral medications on the same day. Viral suppression was defined as most 
recent viral load ≤400 copies/mL. Dates of death were obtained from clinic sources and 
regular matches against the Social Security Death Index.
Analysis
We estimated the proportion of the cohort in each stage of the care continuum over time, 
stratified by history of IDU. Complete details of our approach are available in appendix A. 
Briefly, we estimated the cumulative incidence from enrollment to the following events, 
nonparametrically [14]. Events in bold correspond to transition into a continuum state 
(regardless of prior state); events in italics correspond to transition out of a continuum state 
(regardless of future state).
1. Death before ART initiation;
2. LTC before ART initiation;
3. No longer LTC before ART initiation (composite outcome of return-to-
clinic and death prior to return-to-clinic);
4. ART initiation;
5. Viral suppression after ART initiation;
6. No longer virally suppressed after ART initiation (composite outcome 
including viral load measurement >400 copies/mL, death, or LTC);
7. LTC after ART initiation;
8. No longer LTC after ART initiation; and
9. Death after ART initiation.
Note that ART initiation corresponds to transition into the continuum state “on ART and not 
suppressed” only if ART initiation is not also accompanied by viral suppression or death on 
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the same day. Events other than ART initiation and death could occur more than once in the 
analysis. The maximum numbers of occurrences of each event in our data are available in 
Appendix A Table 1. By estimating cumulative incidence functions, we have appropriately 
accounted for competing events (i.e., events that preclude occurrence of the event of 
interest). For example, death prior to ART initiation precludes a patient from ever initiating 
ART; the cumulative incidence function for ART initiation can only ever go up to (100 – D)
% where D is the cumulative incidence of death before ART initiation. Competing event(s) 
for each continuum-related event are listed in Appendix A Table 1.
The cumulative incidence for events above represent the proportion entering and exiting 
each of the continuum stages. To estimate the proportion present in each continuum stage, 
we added and subtracted cumulative incidence curves [16, 17] as follows:
1. Dead before ART initiation = cumulative incidence of death prior to ART 
initiation.
2. LTC before ART initiation = sum of cumulative incidences for LTC before 
ART initiation, less the sum of the cumulative incidences for no longer 
LTC before ART initiation.
3. Dead after ART initiation = cumulative incidence of death after ART 
initiation.
4. LTC after ART initiation = sum of the cumulative incidences for LTC after 
ART initiation, less the sum of the cumulative incidences for no longer 
LTC after ART initiation.
5. On ART, virally suppressed = sum of the cumulative incidences of viral 
suppression on ART, less the sum of the cumulative incidences of no 
longer being virally suppressed.
6. On ART and not suppressed = cumulative incidence of ART initiation, less 
the cumulative incidences of death after ART initiation, LTC after ART 
initiation, and virally suppressed on ART.
7. In care and not on ART = 1 minus the cumulative incidence of death 
before ART initiation, minus the proportion LTC before ART initiation (#2 
in this list), minus the cumulative incidence of ART initiation.
By design, the proportions above sum to 1 at each time point. Thus we can present the 
distribution of the cohort over time since enrollment as a set of stacked curves. Integrating 
the area between adjacent curves (or equivalently, the area under each individual curve 
graphed separately) gives the (restricted) mean time spent in each continuum stage (or the 
mean months of life lost) over 10 years of follow-up. Here, the term “restricted” is used to 
clarify that the total follow-up time is capped at 10 years, and thus the average time in each 
state is smaller than it would be had we been able to follow everyone from enrollment until 
death. We estimated the restricted mean time in state empirically, and then took the 
difference in estimates for PWID and non-IDU.
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We compare our metric to the difference in the proportion of PWID and non-IDU in each 
stage of the care continuum at 10 years. This latter quantity is similar to traditional care 
continuum estimates in that it provides a snapshot of the population at a specific time, 
however it is anchored to time since clinic enrollment, rather than to calendar time.
We used inverse probability weights [18, 19] to adjust for sex, black race, MSM 
transmission risk, and baseline age, CD4 cell count, HIV1 viral load, AIDS diagnosis and 
antiretroviral therapy exposure. Adjustment served to balance the distribution of these 
covariates among PWID and non-IDU at clinic enrollment, such that adjusted results are not 
due to differences in demographics or initial care-seeking behavior of PWID and non-IDU.
To examine changes in the continuum over calendar time we stratified the cohort according 
to year of enrollment (2000-2003, 2004-2007 and 2008-2014) and compared the difference 
in 5-year restricted mean time spent in each stage of the care continuum associated with IDU 
for each enrollment cohort.
We formed 95% Wald confidence intervals using standard error estimated by the standard 
deviation of estimates based on 200 non-parametric bootstrap resamples of the data [20]. We 
conducted all analyses in SAS 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Of 1,443 ART-naïve, virally unsuppressed, HIV-infected persons enrolled in the JHHCC 
between January 2000 and August 2015, the majority were male (65%), black (77%) and 
heterosexual (57%). Median age at enrollment was 40 years [interquartile range (IQR): 34, 
46], median CD4 count was 284 cells/μL (IQR: 119, 477) and median log10 HIV viral load 
was 4.4 copies/mL (IQR: 3.8, 5.0). One third of persons (33%) had prior exposure to 
antiretroviral medications and 21% had a prior AIDS diagnosis. PWID composed 32% of 
the study sample. PWID were slightly older than non-IDU and fewer reported MSM or 
heterosexual sex as another possible risk factor for HIV infection (Table 1).
During the ten years following enrollment in the JHHCC, both non-IDU and PWID spent 
the most time in any one continuum stage, on ART and virally suppressed (44.9 and 27.9 
months, respectively) (figure 1, table 2). However, this represented only 37% and 23% of 
total person-time for non-IDU and PWID. On average, PWID spent 17.0 fewer months (95% 
CI: −21.2, −12.8) on ART and virally suppressed compared to non-IDU. In contrast, PWID 
lost 8.9 more months of life, spent 5.0 more months on ART but not virally suppressed (95% 
CI: 2.4, 7.6) and spent 5.5 more months in care but not on ART (95% CI: 3.0, 7.9) (table 3). 
PWID spent 4.9 fewer months lost-to-clinic after ART initiation, but that may not be 
attributable to better retention; PWID had lower incidence of ART initiation and higher 
incidence of death after ART initiation. Results from the weighted analysis were similar to 
unweighted results.
Comparing the proportion of PWID and non-IDU in each stage of the care continuum at 10 
years after enrollment resulted in similar substantive conclusions: PWID were less likely to 
be on ART and virally suppressed. However, the relative magnitude of differences between 
PWID and non-IDU differed. For example, while PWID spent 5% more person-time over 10 
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years of follow-up in care but not yet on ART (Table 2), at the end of 10 years, 4% fewer 
PWID were in care but not yet on ART (Supplemental Table 1). In contrast, while PWID 
spent 4% more person-time over 10 years on ART but not virally suppressed, at the end of 
10 years, the proportion of PWID on ART but not virally suppressed was 7% higher than 
among non-IDU.
There were increases in the 5-year restricted mean time spent on ART and virally suppressed 
for both PWID and non-IDU from the 2000-2003 enrollment cohort (9.8 and 17.8 months, 
respectively) to the 2008-2014 enrollment cohort (17.6 and 28.0 months, respectively). 
However, differences in 5-year restricted mean time in each continuum stage comparing 
PWID with non-IDU were similar across all enrollment cohorts (Figure 2, Table 3). For 
example, the difference in months spent on ART and virally suppressed was −8.0 (95% CI: 
−10.9, −5.2) for the 2000-2003 enrollment cohort, and −10.3 (95% CI: −14.5, −6.1) for the 
2008-2014 enrollment cohort. Thus while overall HIV care continuum outcomes improved, 
the disparity in outcomes between PWID and non-IDU did not.
DISCUSSION
PWID and non-IDU spent only 23% and 37% of 10-years of follow-up on ART and virally 
suppressed. If we exclude years lost to death from the denominator, PWID and non-IDU 
spent only 28% and 41% of alive follow-up on ART and virally suppressed. If we exclude 
person-time lost to death or LTC (include only person-time in care), 56% (44.9/79.8 months) 
and 38% (27.9/73.3 months) of follow-up time was spent on ART and virally suppressed by 
non-IDU and PWID, respectively. In contrast, excluding persons who were dead or LTC 
from the denominator, 79% of non-IDU and 65% of PWID were on ART and virally 
suppressed at 10 years after clinic enrollment. In a traditional cross-sectional cascade 
analysis for 2009, 40% of non-IDU and 34% of PWID in the United States who were HIV-
infected and who had initiated HIV-care were virally suppressed on ART [21]. While our 
analysis reached substantively similar conclusions for comparing non-IDU and PWID, the 
two quantities measure different constructs (person-time versus proportion of a population) 
in different populations (a clinical cohort versus a population). Recently, McNairy et al. 
compared the care continuum in four African countries using traditional continuum 
estimates and a new “comprehensive HIV care continuum” that shared several features with 
our approach (namely following persons longitudinally from when they are “at risk” for care 
continuum outcomes). Their conclusions comparing the four countries were substantively 
different depending on the approach used, demonstrating that longitudinal and traditional 
approaches yield different but complementary information [22].
Despite improvements in nearly all stages in the HIV care continuum across enrollment 
cohorts, there was an apparent increase in the restricted mean time spent LTC after ART 
initiation in 2008-2014. We believe that to be, in part, an artifact of the data, and in part, due 
to changing clinical practice. Clinical guidelines released in 2013 suggested that people who 
were adherent to ART and virally suppressed could be seen in clinic every 6 months and 
have viral load and CD4 cell count monitored every 6-12 months [23]. With traditional 
markers of being “in care” assessed less frequently, the potential for people who are on ART 
and virally suppressed to be classified as LTC will increase [13]. We do not have reason to 
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suspect that missing visit data or changes in clinical management are differential according 
to history of IDU, however, and relative differences in restricted mean time should still lead 
to correct inference.
Once persons are virally suppressed their ability to transmit their infection is negligible [1, 
24]. One strength of this analysis is that it yields a measure of person-time spent virally 
unsuppressed, which may give an idea of the relative potential impact of PWID and non-
IDU on the HIV epidemic through their ability to transmit infection. If we assume that 
individuals LTC were not in care, on average PWID spent 6.02 of 10 years capable of 
transmitting infection (12.1+25.9+19.5+14.7 months/12 months/year, from table 3), and 
non-IDU spent 5.35 of 10 years capable of transmitting infection. Given the sample size in 
this analysis, that translates into 2744 and 5280 person-years at risk of transmission for 
PWID and non-IDU, respectively. If we instead assume that individuals lost-to-clinic were in 
care, on ART and virally suppressed elsewhere (i.e., transferred care to another clinic), on 
average PWID and non-IDU spent 3.78 and 2.92 of 10 years capable of transmitting 
infection, and contributed 1725 and 2879 total infectious person-years to the community. 
(These two assumptions represent the lower and upper bounds for infectious person-years.) 
Thus, although on average, an individual PWID spends more time capable of transmitting 
virus, greatest potential for transmission overall comes from non-IDU.
There is increasing appreciation of limitations of the care continuum as currently estimated 
[13, 25, 26] in that it does not capture patients’ transition through continuum stages nor 
follow the same population over time. Furthermore, there is movement towards developing a 
complementary, longitudinal assessment of the HIV care continuum [22, 25]. Our work is 
one of the first patient-centric, longitudinal presentations of the HIV care continuum and, 
while similar to other models, has unique strengths. Our approach summarizes patients’ 
experience across all of follow-up rather than at only one point in time. Furthermore, our 
approach corresponds directly to a public health priority: to reduce the amount of time 
people spend capable of transmitting HIV infection. Our approach is based on a multistate 
model framework. While it is relatively easy to implement, its utility for informing future 
mathematical models of the continuum may be limited compared to a more explicit 
multistate model approach. We compare our approach to other longitudinal continuum 
analyses in appendix B.
Our analysis remains limited in that we could not follow patients after LTC to appropriately 
stage them in the care continuum (other than for mortality). It is possible that patients LTC 
from the JHHCC entered HIV care elsewhere. Applying this approach to a population-based 
cohort may improve upon this potential misclassification error, but even population-based 
data may misclassify persons lost-to-follow-up as out of care if they migrate out of the 
catchment area [27].
We present a novel, patient-centric, longitudinal approach to estimating progression through 
the HIV care continuum. Information from this approach provides supplemental information 
for evaluating health systems’ success at retaining patients in care, initiating them on ART, 
and achieving viral suppression. PWID are not spending substantially more time LTC after 
enrollment in clinical care than non-IDU. Rather PWID in care are spending less time on 
LESKO et al. Page 7













ART, and once on ART, they spend less time virally suppressed. Efforts to increase viral 
suppression among PWID should focus on increasing ART initiation and improving 
adherence to therapy.
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APPENDIX A
Our goal was to estimate the proportion of the cohort in each of the h = 1,...,7 stages of the 
care continuum over time, stratified by history of IDU, x ∈ {0,1}. We represent this 
proportion as Gxh(t). To simplify notation, we suppress the subscript x where unnecessary. 
To obtain Gh(t) we first estimated time to transition between several of the states. There are 
many different transitions possible between states (figure 1), but we focused on estimating 
the time to nine continuum-related events. For each patient i = 1...N we measured time Tijkj 
from enrollment to administrative censoring on August 31, 2015 or at 10 years of follow-up, 
occurrence of a competing event (competing events for each outcome are listed in table 1), 
or occurrence of each of k = 1...Kj instances of j = 1...9 continuum-related events. Of the 
following nine events, those in bold correspond to transition into a continuum state 
(regardless of prior state); events in italics correspond to transition out of a continuum state 
(regardless of future state).
1. Death before ART initiation;
2. LTC before ART initiation;
3. No longer LTC before ART initiation (composite outcome of return-to-
clinic and death prior to return-to-clinic);
4. ART initiation;
5. Viral suppression after ART initiation;
6. Viral failure after ART initiation and viral suppression (composite 
outcome including viral load measurement >400 copies/mL, death, or 
LTC);
7. LTC after ART initiation;
8. No longer LTC after ART initiation (composite outcome of return-to-clinic 
and death prior to return-to-clinic); and
9. Death after ART initiation.
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ART initiation does not correspond to transition into one specific continuum state because 
we split ART initiators further into those who were in care and virally suppressed, in care 
and not virally suppressed, LTC, or dead. Events other than death could occur more once in 
the analysis. Kj for each event was based on the maximum number of events of type j in the 
data (table 1). All events have at least one competing event (table 1). For each of the ΣJKj 
events, in addition to Tijkj, we assigned an event indicator Δijkj that was equal to 1 for an 
event of type j, 2 for a competing event, and 0 for administrative censoring.
We estimated the cumulative incidence function for each event, Rĵkj(t), nonparametrically 
[14]. To estimate the proportion in each stage of the care continuum over time Ĝh(t), we 
added and subtracted cumulative incidence curves [16, 17] as follows:
1. Dead before ART initiation: ĜH=1(t)=R̂J=1(t)
2. LTC before ART initiation: 
3. Dead after ART initiation: ĜH=3(t)=R̂J=9(t)
4.
LTC after ART initiation: 
5. On ART, virally suppressed: 
6. On ART, not suppressed: ĜH=6(t)=R̂J=4(t) – ĜH=3(t) – ĜH=4(t) – ĜH=5(t)
7. In care, not on ART: ĜH=7(t)= 1 – R̂J=4(t) – ĜH=1(t) – ĜH=2(t)
By design, . Thus we can present the distribution of the cohort over time 
since enrollment as a set of stacked curves. The area between adjacent curves (or 
equivalently, the area under each individual curve graphed separately) is interpretable as the 
mean time that an average patient spends in each continuum stage over 10 years of follow-
up. The area under the (cumulative incidence) curves for death are interpretable as the mean 
months of life lost over 10 years of follow-up. We estimate the restricted mean time in state 
h empirically as . When time is discrete, because the cumulative 
incidence functions are step-functions, this interval can be calculated as the Riemann sum 
 where d indexes days of follow-up over the 10-year period. We 
estimated the difference in restricted mean time comparing PWID to non-IDU by 
. We present the distribution of total follow-up time across each of 
the care continuum stages  and the proportion of the PWID and non-IDU in each 
stage of the care continuum at 10 years. This latter quantity is akin to traditional care 
continuum estimates in that it is a snapshot of population at a specific point in time. It is 
different from traditional care continuum estimates in that it is anchored to time since clinic 
enrollment, rather than to calendar time. We also compare inference with respect to the 
continuum experience of PWID versus non-IDU using differences in restricted mean time in 
each continuum stage, and differences in proportions in each continuum stage at 10 years.
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To get adjusted estimates, we followed the approach described above, but weighted each 
observation by the inverse probability that the individual reported IDU as a probable route of 
HIV acquisition X, conditional on covariates L [18, 19]. Weights were constructed as 
 where the vector L contains all the baseline covariates listed 
in the methods section. Probabilities were estimated using logistic regression. All continuous 
covariates were entered into the model using restricted quadratic splines with knots at the 
5th, 35th, 65th, and 95th percentiles [28]. HIV viral load was log-transformed before creating 
splines.
Appendix Figure 1. 
HIV care continuum states and allowable movement through the continuum under the 
proposed model
* Note that individuals were allowed to move directly from being lost-to-clinic prior to ART 
initiation or in care, not on ART initiation into being on ART and virally suppressed; this 
could have occurred if observation of ART initiation and viral suppression occurred 
simultaneously, e.g. if person was virally suppressed on mono- or dual- therapy and then 
initiated ART, or if viral suppression occurred in the same month as ART initiation among 
ART-naïve persons.
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McNairy et al. proposed a similar longitudinal approach to the continuum in which they use 
survival methods to report the proportion of patient outcomes at 3, 6 and 12 months after 
enrollment into HIV care that were optimal, sub-optimal, or poor [22]. Haber et al. used a 
similar approach, summarizing the distribution of the population 2 years after enrollment 
[29]. A strength McNairy's and our approach is that both consider outcomes of patients who 
do not initiate ART. Our approach has an additional advantage over both prior longitudinal 
approaches in that it provides a means for summarizing the distribution of person-time 
across all of follow-up, rather than requiring the user select a single follow-up time and 
report the distribution of the population across continuum stages at a cross-sectional point in 
time after enrollment. Our approach is based in a multistate model framework [16, 17] yet 
does not require fitting multistate models. The work of Lee et al. [30] and framework by 
Powers & Miller [26] approach the continuum from a more formal multistate model 
framework, which may prove useful for future mathematical models of the continuum.
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Table 1
Characteristics of 1,443 ART-naïve, virally unsuppressed, HIV-infected persons who enrolled in the Johns 
Hopkins HIV Clinical Cohort from 2000-2014, stratified by self-report of injection drug use as their likely 
route of HIV acquisition
PWID Non-IDU Total
N 456 987 1443
Male sex
† 291 (64%) 641 (65%) 932 (65%)
Age
‡ 42 (37, 48) 38 (31, 47) 40 (34, 46)
Race
    Black 357 (78%) 751 (76%) 1108 (77%)
    White 89 (20%) 187 (19%) 276 (19%)
    Other 10 (2%) 49 (5%) 59 (4%)
Transmission risk
    MSM 34 (7%) 329 (33%) 363 (25%)
    Heterosexual 222 (49%) 597 (60%) 819 (57%)
History of any antiretroviral use 151 (33%) 320 (32%) 471 (33%)
AIDS 108 (24%) 198 (20%) 306 (21%)
CD4 cell count (cells/μl)
‡ 273 (104, 451) 296 (126, 482) 284 (119, 477)
    <50 78 (17%) 167 (17%) 245 (17%)
    50-199 cells/μL 101 (23%) 195 (20%) 296 (21%)
    200-349 103 (23%) 218 (22%) 321 (23%)
    ≥350 cells/μl 165 (37%) 390 (40%) 555 (39%)
    Missing 9 17 26
Viral load (HIV RNA log10 copies/mL)
‡ 4.5 (3.8, 5.0) 4.4 (3.7, 5.0) 4.4 (3.8, 5.0)
* Abbreviations: HIV, human immunodeficiency virus; PWID, persons who inject drugs; IDU, injection drug use; MSM, men who have sex with 
men; BMI, body mass index; ART, antiretroviral therapy (defined as initiating 3+ drugs on the same day); AIDS, acquired immune deficiency 
syndrome
§ As measured by any positive laboratory test for antibody, antigen, or DNA/RNA
†
N(%) unless otherwise specified
‡
Median (IQR)
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